Widely used:Recently Viewed
Clear All
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$1,906 Mln
P/E Ratio
30.23
P/B Ratio
1.43
Industry P/E
--
Debt to Equity
0.51
ROE
0.05 %
ROCE
3.23 %
Div. Yield
0 %
Book Value
24.14
EPS
1.16
CFO
$449.20 Mln
EBITDA
$1,200.67 Mln
Net Profit
$-952.22 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
LivaNova (LIVN)
| -23.17 | -9.33 | -25.84 | -33.10 | -24.18 | -5.50 | -5.79 |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
LivaNova (LIVN)
| -6.84 | -36.47 | 32.05 | -12.22 | -17.54 | 14.37 | 77.72 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The... Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom. Address: 20 Eastbourne Terrace, London, United Kingdom, W2 6LG Read more
Chief Financial Officer
Mr. Alex Shvartsburg
Chief Financial Officer
Mr. Alex Shvartsburg C.M.A.
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of LivaNova PLC (LIVN) stood at $ 2,506 Mln as on 31-Dec-24
The share price of LivaNova PLC (LIVN) is $35.58 (NASDAQ) as of 17-Apr-2025 16:00 EDT. LivaNova PLC (LIVN) has given a return of -24.18% in the last 3 years.
LivaNova PLC (LIVN) has a market capitalisation of $ 1,906 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of LivaNova PLC (LIVN) is 30.23 times as on 17-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the LivaNova PLC (LIVN) and enter the required number of quantities and click on buy to purchase the shares of LivaNova PLC (LIVN).
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; and devices that deliver neuromodulation therapy for treating difficult-to-treat depression and drug-resistant epilepsy. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its medical devices through a combination of direct sales representatives, agents, and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom. Address: 20 Eastbourne Terrace, London, United Kingdom, W2 6LG
The CEO & director of Mr. Alex Shvartsburg. is LivaNova PLC (LIVN), and CFO & Sr. VP is Mr. Alex Shvartsburg C.M.A..
There is no promoter pledging in LivaNova PLC (LIVN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| LivaNova PLC (LIVN) | Ratios |
|---|---|
|
Return on equity(%)
|
4.87
|
|
Operating margin(%)
|
12.08
|
|
Net Margin(%)
|
5.04
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of LivaNova PLC (LIVN) was $0 Mln.
$0.51
(
